Revolution Medicines, Inc.

NasdaqGS:RVMD 주식 보고서

시가총액: US$9.2b

Revolution Medicines 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Mark Goldsmith

최고 경영자

US$10.4m

총 보상

CEO 급여 비율6.1%
CEO 임기10yrs
CEO 소유권0.4%
경영진 평균 재임 기간6.5yrs
이사회 평균 재임 기간7.9yrs

최근 관리 업데이트

Recent updates

Calculating The Intrinsic Value Of Revolution Medicines, Inc. (NASDAQ:RVMD)

Sep 28
Calculating The Intrinsic Value Of Revolution Medicines, Inc. (NASDAQ:RVMD)

This Is Why Revolution Medicines, Inc.'s (NASDAQ:RVMD) CEO Compensation Looks Appropriate

Jun 15
This Is Why Revolution Medicines, Inc.'s (NASDAQ:RVMD) CEO Compensation Looks Appropriate

Revolution Medicines: On Hold Pending A Lower Entry Point

Jun 04

Revolution Medicines: An Expensive Shot At A Massive Market Opportunity

Apr 12

Revolution Medicines Is Hard To Understand

Feb 01

Here's Why We're Not Too Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Situation

Aug 09
Here's Why We're Not Too Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Situation

Some Analysts Just Cut Their Revolution Medicines, Inc. (NASDAQ:RVMD) Estimates

May 13
Some Analysts Just Cut Their Revolution Medicines, Inc. (NASDAQ:RVMD) Estimates

We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth

Apr 02
We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth

We're Hopeful That Revolution Medicines (NASDAQ:RVMD) Will Use Its Cash Wisely

Dec 20
We're Hopeful That Revolution Medicines (NASDAQ:RVMD) Will Use Its Cash Wisely

We're Not Very Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Rate

Sep 15
We're Not Very Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Rate

Revolution Medicines promotes Jack Anders to CFO

Sep 02

New Forecasts: Here's What Analysts Think The Future Holds For Revolution Medicines, Inc. (NASDAQ:RVMD)

Aug 10
New Forecasts: Here's What Analysts Think The Future Holds For Revolution Medicines, Inc. (NASDAQ:RVMD)

Revolution Medicines to raise up to $200M in stock offering

Jul 19

CEO 보상 분석

Mark Goldsmith 의 보수는 Revolution Medicines 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$519m

Mar 31 2024n/an/a

-US$484m

Dec 31 2023US$10mUS$631k

-US$436m

Sep 30 2023n/an/a

-US$331m

Jun 30 2023n/an/a

-US$296m

Mar 31 2023n/an/a

-US$259m

Dec 31 2022US$7mUS$607k

-US$249m

Sep 30 2022n/an/a

-US$245m

Jun 30 2022n/an/a

-US$224m

Mar 31 2022n/an/a

-US$208m

Dec 31 2021US$8mUS$581k

-US$187m

Sep 30 2021n/an/a

-US$169m

Jun 30 2021n/an/a

-US$143m

Mar 31 2021n/an/a

-US$126m

Dec 31 2020US$2mUS$554k

-US$110m

Sep 30 2020n/an/a

-US$95m

Jun 30 2020n/an/a

-US$85m

Mar 31 2020n/an/a

-US$71m

Dec 31 2019US$5mUS$504k

-US$62m

Sep 30 2019n/an/a

-US$57m

Dec 31 2018US$1mUS$490k

-US$49m

보상 대 시장: Mark 의 총 보상 ($USD 10.41M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 8.06M ).

보상과 수익: 회사가 수익성이 없는 동안 Mark 의 보상이 증가했습니다.

CEO

Mark Goldsmith (62 yo)

10yrs

테뉴어

US$10,411,247

보상

Dr. Mark A. Goldsmith, M.D., Ph.D. is the Chief Executive Officer, President and Director of Revolution Medicines, Inc. since November 2014 and serves as its Chairman. Dr. Goldsmith served as a Venture Par...

리더십 팀

이름위치테뉴어보상소유권
Mark Goldsmith
CEO, President & Chairman10yrsUS$10.41m0.38%
$ 34.6m
Jack Anders
Chief Financial Officer6.3yrsUS$3.05m0.029%
$ 2.7m
Margaret Horn
Chief Operating Officer6.1yrsUS$4.39m0.033%
$ 3.0m
Stephen Kelsey
President of Research & Development7.7yrsUS$4.39m0.11%
$ 9.8m
Xiaolin Wang
Executive Vice President of Development6.7yrsUS$3.23m0.015%
$ 1.4m
Martin Burke
Co-Founder & Chairman of Scientific Advisory Boardno data데이터 없음데이터 없음
Michael Fischbach
Academic Co-Founder & Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Kevan Shokat
Academic Co-Founder & Member of Scientific Advisory Board7.9yrs데이터 없음데이터 없음
Walter Reiher
Chief Information Officerno data데이터 없음데이터 없음
Jan Smith
Chief Scientific Officer1.3yrs데이터 없음데이터 없음
Erin Graves
Senior Director of Corporate Communications & Investor Relationsno data데이터 없음데이터 없음
Jeff Cislini
Senior VP2.2yrs데이터 없음0.0032%
$ 299.1k

6.5yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: RVMD 의 관리팀은 노련하고 경험 (평균 재직 기간 6.5 년)입니다.

이사회 구성원

이름위치테뉴어보상소유권
Mark Goldsmith
CEO, President & Chairman10yrsUS$10.41m0.38%
$ 34.6m
Martin Burke
Co-Founder & Chairman of Scientific Advisory Boardno data데이터 없음데이터 없음
Michael Fischbach
Academic Co-Founder & Member of Scientific Advisory Board8.4yrs데이터 없음데이터 없음
Kevan Shokat
Academic Co-Founder & Member of Scientific Advisory Board7.9yrs데이터 없음데이터 없음
Julian Adams
Senior Advisor & Member of Scientific Advisory Board7.9yrs데이터 없음데이터 없음
Alexis Borisy
Lead Independent Director10yrsUS$510.63k1.4%
$ 128.4m
Eric Gordon
Senior Advisor & Member of Scientific Advisory Board8.4yrs데이터 없음데이터 없음
John Kuriyan
Senior Advisor & Member of Scientific Advisory Board7.9yrs데이터 없음데이터 없음
Lorence Kim
Independent Director2.3yrsUS$489.99k0.037%
$ 3.4m
Thilo Schroeder
Independent Director6.7yrs데이터 없음데이터 없음
Elizabeth Anderson
Independent Director9.7yrsUS$483.78k0.026%
$ 2.4m
Trever Bivona
Senior Advisor & Member of Scientific Advisory Board7.9yrs데이터 없음데이터 없음

7.9yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 이사회: RVMD 의 이사회는 경험(평균 재직 기간 7.9 년)으로 간주됩니다.